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The bat sarbecovirus RaTG13 is a close relative of SARS-CoV-2, the cause of the COVID-19
pandemic. However, this bat virus was most likely unable to directly infect humans since its
Spike (S) protein does not interact efficiently with the human ACE2 receptor. Here, we show
that a single T403R mutation increases binding of RaTG13 S to human ACE2 and allows VSV
pseudoparticle infection of human lung cells and intestinal organoids. Conversely, mutation of
R403T in the SARS-CoV-2 S reduces pseudoparticle infection and viral replication. The
T403R RaTG13 S is neutralized by sera from individuals vaccinated against COVID-19 indi-
cating that vaccination might protect against future zoonoses. Our data suggest that a
positively charged amino acid at position 403 in the S protein is critical for efficient utilization
of human ACE2 by S proteins of bat coronaviruses. This finding could help to better predict
the zoonotic potential of animal coronaviruses.
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S ince its first occurrence in December 2019, SARS-CoV-2,the causative agent of COVID-19, has infected more than220 million people by September 2021 and caused a global
health and economic crisis1,2. SARS-CoV-2 belongs to the Sar-
becovirus subgenus of betacoronaviruses, which are mainly found
in bats3,4. Horseshoe bats (Rhinolophidae) also harbour viruses
that are closely related to SARS-CoV-1 that infected about 8.000
people in 2002 and 20033,4. The bat virus RaTG13 sampled from
a Rhinolophus affinis horseshoe bat in 2013 in Yunnan has been
identified as one of the closest relatives of SARS-CoV-2, showing
approximately 96% sequence identity throughout the genome1.
Thus, SARS-CoV-2 most likely originated from horseshoe bats1,2,
although it has been proposed that cross-species transmission to
humans may have involved pangolins as secondary intermediate
host5,6.
The Spike (S) proteins of both SARS-CoV-1 and SARS-CoV-2
utilize the angiotensin-converting enzyme 2 (ACE2) receptor to
enter human target cells7–10. The ability to use a human receptor
for efficient infection is a key prerequisite for successful zoonotic
transmission. Although the RaTG13 S protein is highly similar to
the SARS-CoV-2 S it does not interact efficiently with the human
ACE2 receptor11, suggesting that this bat virus would most likely
not be able to infect humans directly. It has been reported that
specific alterations in the receptor-binding domain (RBD)12, as
well as a four-amino-acid insertion (PRRA) introducing a furin-
cleavage site7,13, play a key role in efficient ACE2 utilization and
consequently the high infectiousness and efficient spread of
SARS-CoV-2. Here we show, which specific features allow the S
proteins of bat CoVs to use human ACE2 for efficient entry and
thus to successfully cross the species barrier to humans.
Results
Computational analysis suggests that R403 contributes to
Spike interaction with human ACE2. Previous simulations
suggested that R403 is involved in intramolecular interactions
stabilizing the SARS-CoV-2 S trimer interface11 and contributes
significantly to the strength of SARS-CoV-2 RBD interaction with
the human ACE2 receptor14–16. We found that R403 is highly
conserved in SARS-CoV-2 S proteins: only 294 of ~3.4 million S
sequences recorded on GSAID contain a conservative change of
R403K and just 132 another amino acids: M (78), H (16), G (10),
S (10), T (6), I (9), L (2), N (2), P (1) or W (1). Once residue 403
was deleted. Notably, the presence of a positively charged residue
at position 403 distinguishes the S proteins of SARS-CoV-1
(K403) and SARS-CoV-2 (R403) from the bat CoV RaTG13 S
protein (T403) (Fig. 1a). Molecular modelling of S/ACE2 inter-
action using reactive force field simulations confirmed the
establishment of close proximity and putative charge interactions
between R403 in the SARS-CoV-2 S with E37 in the human
ACE2 receptor (Fig. 1b). These analyses predicted that mutation
of T403R significantly strengthens the ability of the RaTG13 S
protein to bind human ACE2 (Fig. 1c and Supplementary
Movies 1 and 2).
Mutation of T403R allows RaTG13 S to use human ACE2 as
entry receptor. To verify the functional importance of residue
403 for ACE2 usage by CoV S proteins, we used VSV particles
(VSVpp) pseudotyped with parental and mutant S proteins.
Mutation of R403T reduced the ability of the SARS-CoV-2 S
protein to mediate entry of VSVpp into the human colorectal
adenocarcinoma cell line Caco-2 by 40% (Fig. 2a). Strikingly, the
T403R change enhanced the infectiousness of Vesicular stomatitis
virus pseudoparticles (VSVpp) carrying the RaTG13 S for Caco-2
cells ~30-fold, while substitution of T403A introduced as control
had no enhancing effect (Fig. 2a). Similar results were obtained in
the human lung cancer cell line Calu-3 (Fig. 2b) and the lung
carcinoma cell line A549 that required overexpression of ACE2
(Fig. 2c; Supplementary Fig. 1). Coexpression of the transmem-
brane serine protease 2 (TMPRSS2) enhanced infection mediated
by the wildtype (WT) and R403T SARS-CoV-2 S proteins but had
no significant effect on entry mediated by the RaTG13 T403R S
(Fig. 2c). To assess whether the T403R change might allow the bat
CoV RaTG13 to spread to human bs, we performed infection
studies using intestinal organoids derived from pluripotent stem
cells. The parental SARS-CoV-2 S protein allowed efficient
infection of gut organoids17 and the R403T change had modest
attenuating effects (Fig. 2d and Supplementary Fig. 2). In con-
trast, the parental RaTG13 S protein did not mediate VSVpp
entry, while the T403R S allowed significant infection of human
intestinal cells (Fig. 2d; Supplementary Fig. 2).
Cell-to-cell fusion assays showed that coexpression of the
SARS-CoV-2 S and human ACE2 resulted in the formation of
large syncytia (Supplementary Fig. 3). The parental and T403A
RaTG13 S did not lead to detectable fusion. However, significant
syncytia formation was observed for the T403R RaTG13 S
(Supplementary Fig. 3). In line with the VSVpp results,
complementation of a full-length recombinant SARS-CoV-2
lacking the S ORF (SCoV-2ΔS, replicon System) in ACE2-
expressing HEK293T cells with WT SARS-CoV-2 S led to virus-
induced cytopathic effects (CPE) indicating successful virus
production and propagation (Fig. 2e). Mutation of R403T in
the SARS-CoV-2 S reduced CPE. The WT and T403A RaTG13 S
were unable to complement SCoV-2ΔS, while the T403R RaTG13
S resulted in significant CPE. Expression of a Gaussia luciferase
(GLuc) from S variant complemented recombinant SCoV2ΔS-
GLuc confirmed the importance of R403 for viral spread (Fig. 2f).
To assess the relevance of R403 for SARS-CoV-2 replication, we
reconstituted replication-competent SARS-CoV-2 using bacmids
specifically containing the R403T mutation and coding for the
yellow fluorescent protein (YFP) in place of ORF618. R403T S was
efficiently expressed and incorporated into viral particles, albeit at
slightly reduced levels compared to the WT SARS-CoV-2 S
(Supplementary Fig. 4). Infection of Caco-2 cells at low MOI
showed that the R403T SARS-CoV-2 mutant replicated with
significantly lower efficiency than WT virus (Fig. 2g). Thus, data
obtained with replication-competent SARS-CoV-2 confirmed the
results of S-mediated VSVpp infection and the replicon assays.
The enhancing effect of T403R in RaTG13 S depends on E37 in
ACE2. Modelling analyses suggest that R403 promotes
S-mediated infection of human cells because it interacts with E37
in human ACE2 (Fig. 1b). In agreement with the in silico data,
mutation of E37A in ACE2 abolished the enhancing effect of the
T403R change on RaTG13 S-mediated VSVpp infection of
HEK293T cells (Fig. 3a), without affecting ACE2 expression levels
(Fig. 3b). In addition, the substitution of E37A reduced the levels
of WT SARS-CoV-2 S-mediated infection to those mediated by
R403T SARS-CoV-2 S (Fig. 3a). In comparison, mutation of
D38A in ACE2 predicted to play little if any role in S interaction
did not disrupt the enhancing effect of the T403R change on
RaTG13 S-mediated VSVpp infection.
To examine the role of R403 in the S protein on ACE2 binding,
we established an in vitro S-ACE2 interaction assay. Immobilized
ACE2 is incubated with lysates of S-V5 transfected
HEK293T cells (Fig. 3c). S protein retained after washing is
detected by an αV5-Ms and quantified using a secondary HRP-
conjugated anti-mouse Ab. SARS-CoV-2 S was expressed at lower
levels compared to the RaTG13 S (Fig. 3d) but bound efficiently
to human ACE2 (Fig. 3e). The R403T change in SARS-CoV-2 S
moderately reduced and the T403R substitution in RaTG13 S
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strongly enhanced the levels of S protein bound to ACE2 (Fig. 3e).
In the case of SARS-CoV-2 R403T S this effect may be partly due
to reduced S expression levels. The T403R change in RaTG13 S,
however, specifically enhanced ACE2 binding without affecting S
expression levels.
Proteolytic processing of the T403R RaTG13 S protein. Cor-
onavirus entry is a multi-step process and critically dependent on
proteolytic processing of the S protein19. It has been reported that
sequential cleavage of SARS-CoV-2 S first by furin at the S1/
S2 site and subsequently by TMPRSS2 at the S2′ site is required
for efficient infection9,20. The RaTG13 S lacks the poly-basic furin
cleavage site which contributes to the high infectivity of SARS-
CoV-2, while the presumed TMPRSS2 cleavage site is conserved
(Fig. 4a). Western blot analyses showed that the mutant S pro-
teins were efficiently expressed and incorporated into VSVpp
(Fig. 4b). Predictably, cleavage at the S1/S2 site was less efficient
for RaTG13 compared to the SARS-CoV-2 S proteins (Fig. 4b).
SARS-CoV-2 replicates in ACE2 expressing cells and it has been
reported that the interaction of the S protein with ACE2 pro-
motes proteolytic processing21,22. Indeed, ACE2 coexpression
induced processing of the WT and R403T SARS-CoV-2 as well as
T403R RaTG13 S2 proteins to S2′, while cleavage of the WT and
T403A RaTG13 S proteins remained inefficient (Fig. 4b).
R403 generates a potential RGD integrin-binding site in the
viral Spike protein and it is under debate whether the ability of
the SARS-CoV-2 S to use integrins as viral attachment factors
may play a role in its high infectiousness23–25. We found
that the integrin inhibitor ATN-161 had no definitive effect
on SARS-CoV-2 or T403R RaTG13 S-mediated infection of
Caco-2 cells (Supplementary Fig. 5) reported to express α5β1
Integrin26. Thus, the enhancing effect of the T403R mutation on
the ability of RaTG13 S to infect human cells seems to be due to
increased interaction with ACE2 rather than the utilization of
integrins.
RaTG13 S-mediated VSVpp infection of A549 cells was equally
effective in the presence or absence of TMPRSS2 (Fig. 2c). It has
been reported that the cysteine proteases Cathepsin B/L can
activate S in the absence of TMPRSS227,28. Indeed, SARS-CoV-2
and T403R RaTG13 S-mediated VSVpp infection of ACE2-A549
cells was efficiently inhibited by the Cathepsin inhibitor E64-d
but not by the TMPRSS2 inhibitor Camostat mesylate (Fig. 4c).
Thus, activation of S2 to S2’ during RaTG13 T403R-dependent
infection of ACE2-A549 cells is mediated by Cathepsins. To
assess which proteases are involved in cell−cell fusion mediated
by the RaTG13 T403R S protein, we examined syncitia formation
in the presence of specific inhibitors. Furin inhibitor 1 prevented
and the Cathepsin inhibitor E64-d moderately reduced both
SARS-CoV-2 and RaTG13 T403R S-mediated cell−cell fusion
(Supplementary Fig. 6). In contrast, the TMPRSS2 inhibitor
Camostat had little if any inhibitory effect. Altogether, mutation
of T403R allows RaTG13 S interaction with human ACE2 and
Fig. 1 Modelling of the interaction of Coronavirus Spike residue 403 with human ACE2. a Schematic representation of the SARS-CoV-2 S protein (top
panel), domains are indicated in different colours. Receptor binding domain (RBD), light green. Receptor binding motif (RBM), dark green. Transmembrane
domain (TM), orange. R403, pink. S1/S2 and S2′ cleavage sites are indicated. Sequence alignment of SARS-CoV-2, SARS-CoV-1, Pan-CoV, and RaTG13
Spike RBD (bottom panel). Sequence conservation is indicated. grey arrows denote important residues for ACE2 binding. b Reactive force field simulation
of SARS-CoV-2 Spike in complex with human ACE2 (PDB: 7KNB (https://www.rcsb.org/structure/7KNB)) (left panel) and focus on position 403 in SARS-
CoV-2 S (R) or RaTG13 S (T) or respective exchange mutants at position 403 (right panel). c Exemplary energy curve of the reactive molecular dynamics
simulation for SARS-CoV-2 S and SARS-CoV-2 S R403T (top panel) and RaTG13 and RaTG13 T430R spike with human ACE2 (bottom panel).
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proteolytic activation by furin and Cathepsins for both cell−cell
fusion and RaTG13 S-mediated VSVpp entry.
The ability of T403R RaTG13 S to utilize ACE2 is species-
specific. To examine the species-specificity of receptor usage by
SARS-CoV-2 and RaTG13 S proteins, we overexpressed human
and bat-derived ACE2 in HEK293T cells and examined their
susceptibility to S-mediated VSVpp infection. The WT SARS-
CoV-2 and the T403R RaTG13 S proteins allowed efficient entry
into cells overexpressing human ACE2, while the parental
RaTG13 S protein was poorly active (Fig. 5a). Both WT SARS-
CoV-2 S and (to a lesser extent) R403T SARS-CoV-2 S proteins
were also capable of using bat (Rhinolophus affinis) ACE2 for
viral entry although the overall infection rates were low (Fig. 5a).
In contrast, the WT RaTG13 S protein used R. pusillus ACE2 with
very poor efficiency and was unable to use R. macrotis ACE2 for
infection, suggesting that RaTG13 might use an alternative
receptor for infection of bat cells. The results agree with the
previous finding that RaTG13 S is able to use human ACE2 to
some extent if overexpressed29 but also confirm that the T403R
change greatly enhances this function and is required for utili-
zation of endogenously expressed human ACE2. To validate the
results obtained with human HEK293T cells, we utilized the lung
epithelial cell line Tb1 Lu1 of Tadarida brasiliensis (Bat31)30. In
Fig. 2 R403 in Spike is crucial for ACE2-dependent entry. a Binary images of CaCo-2 cells transduced with VSVΔG-GFP pseudotyped with SARS-CoV-2,
RaTG13 or indicated mutant S. Successful infection events (=GFP positive cells) displayed as black dots. Scale bar, 1.5 mm and automatic quantification of
infection events by counting GFP positive cells. Bars represent the mean of three independent experiments (±SEM); b automatic quantification of infection
events of Calu-3 cells transduced with VSVΔG-GFP pseudotyped with SARS-CoV-2, RaTG13 or indicated mutant S. Bars represent the mean of three
independent experiments (±SEM). c Automatic quantification of infection events of A459 ACE2 and A459 ACE2 and TMPRSS2 expressing cells
transduced with VSVΔG-GFP pseudotyped with SARS-CoV-2, RaTG13 or indicated mutant S. Bars represent the mean of three independent experiments
(±SEM). d Bright field and fluorescence microscopy (GFP) images of hPSC derived gut organoids infected with VSVΔG-GFP (green) pseudotyped with
SARS-CoV-2, RaTG13, or indicated mutant S (300 µl, 2 h). Scale bar, 250 μm and quantification of the percentage of GFP-positive cells of (a). Bars
represent the mean of three independent experiments (±SEM). e Bright field and fluorescence microscopy (GFP) images of HEK293T cells transfected with
SCoV-2ΔS bacmid, SCoV2-N, ACE2, T7 polymerase and indicated Spike variants. Scale bar, 125 μm. Arrows indicate syncytia. f Quantification of Gaussia
luciferase activity in the supernatant of HEK293T cells expressing SCoV-2ΔS-Gaussia bacmids as described in (c). Bars represent the mean of three
independent experiments (±SEM). g Replication kinetic of Caco-2 cells, infected with either SARS-CoV-2 d6-YFP wild type or SARS-CoV-2 d6-YFP R403T
(MOI 0.005 or 0.02). Supernatants were collected at the indicated time points post-infection, and replication was determined by RT-qPCR. Lines represent
the mean of three independent experiments (±SEM). a−d, f Two-tailed Student’s t-test with Welch’s correction. g Two-tailed Student’s t-test with Welch’s
correction (on area under the curve).
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agreement with the previous finding that this cell line lacks
endogenous ACE2 expression, it did not support infection by
CoV S proteins (Fig. 5b). Engineered expression of human ACE2
rendered Lu 1 highly susceptible to infection mediated by SARS-
CoV-2 and the T403R RaTG13 S proteins (Fig. 5b). In compar-
ison, entry via the R403T SARS-CoV-2 S was strongly attenuated
and the WT and T403A RaTG13 S proteins were unable to
mediate VSV-pp infection.
Sensitivity of T403R RaTG13 S to inhibitors and sera from
vaccinated individuals. The increased infectiousness of the
T403R RaTG13 S enabled us to examine its sensitivity to ther-
apeutic agents and serum neutralization. In agreement with its
reported broad antiviral activity31, the fusion inhibitor EK-1
efficiently inhibited SARS-CoV-2, T403R RaTG13, as well as (to a
much lesser extent) Pangolin CoV S-mediated infection (Fig. 6a).
In contrast, the monoclonal antibody Casirivirab32 was only
active against SARS-CoV-2 S (Fig. 6b). Sera from three indivi-
duals who had received prime-boost treatment with the Pfizer-
BioNTech COVID-19 Vaccine neutralized the T403R RaTG13 S
with higher efficiency than the SARS-CoV-2 S (Fig. 6c). To fur-
ther analyze the sensitivity of the T403R RaTG13 S to neu-
tralization, we examined sera from 22 individuals who received
heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vacci-
nation and nine individuals who received homologous BNT162b2
vaccination. In contrast to the initial experiment (Fig. 6c), VSVpp
stocks were normalized for the same infectivity. We found that all
sera inhibited RaTG13 T403R S-mediated infection abeit with
varying efficiency (Fig. 6d). On average, sera obtained after het-
erologous and homologous vaccination regimens showed similar
neutralization efficiencies against RaTG13 (Fig. 6e) and SARS-
CoV-2 (Fig. 6f). These results suggest that current vaccine regi-
mens against SARS-CoV-2 may protect against future zoonoses
of bat coronaviruses.
Discussion
Our results demonstrate that a single amino acid change of
T403R allows the S protein of RaTG13, one of the closest known
bat relatives of SARS-CoV-2, to utilize human ACE2 for viral
entry. The strong enhancing effect of the T403R change on
RaTG13 S function came as a surprise since five of six different
residues proposed to be critical for SARS-CoV-2 S RBD inter-
action with human ACE2 are not conserved in RaTG13 S12,33.
We show that the effect of T403R on RaTG13 S is due to an
increased ability to interact with E37 on human ACE2, allowing
more efficient receptor binding. Mutation of E37A not only
abolished the enhancing effect of the T403R change on RaTG13
S-mediated VSVpp infection but also reduced infection mediated
by the SARS-CoV-2 S (Fig. 3a). Some individuals show rare
polymorphisms of E37K (frequency: 3.27e−5; gnomAD, https://
gnomad.broadinstitute.org) in ACE2 which was reported to
impair S binding34, similar to the E37A mutant analyzed in the
Fig. 3 The enhancing effect of T403R in RaTG13 S depends on E37 in ACE2. a HEK293T cells expressing indicated ACE2 constructs were infected with
VSVΔG-GFP pseudotyped with SCoV-2, RaTG13, or indicated mutant S. Quantification by automatic counting of GFP positive cells. Bars represent the
mean of three independent experiments (±SEM). Two-tailed Student’s t-test with Welch’s correction. b Mutations introduced into human ACE2 (upper)
and exemplary immunoblot of whole cells lysates (WCLs) of HEK293T cells expressing the indicated ACE2 constructs. Blots were stained with anti-ACE2
and anti-GAPDH and quantified for ACE2 expression (lower panel). Bars represent the mean of three independent experiments (±SEM). c Schematic
representation of the ACE2 interaction assay. d Exemplary immunoblots of WCLs of HEK293T cells expressing SCoV-2 S, RaTG13 S, or the indicated
mutant. Blots were stained with anti-SCoV-2 S, anti-GAPDH, and quantified for Spike expression. e ACE2 binding using whole cell lysates of HEK293T
expressing SARS-CoV-2, RaTG13, or indicated mutant S. Bars represent the mean of three independent experiments (±SEM).
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present study. It is tempting to speculate that these individuals
might have a reduced risk for infection and/or severe COVID-19.
A recent study proposed that residue 501 plays a key role in the
ability of RaTG13 S to use human ACE2 for viral entry35 but the
reported enhancing effect of changes at position 501 was weaker
than that observed for the T403R change analyzed in the present
study. However, the previous finding that numerous residues in
the SARS-CoV-2 S RBD are involved in the interaction with the
human ACE2 orthologue explains why the R403T substitution
only moderately reduced SARS-CoV-2 infection. Mutation of E37
in ACE2 reduced the levels of WT CoV-2 S-mediated infection to
those obtained for the R403T CoV-2 S (Fig. 3a). This suggests
that the interaction between R403 in the S protein and E37 in the
ACE2 receptor is relevant for full infectiousness of SARS-CoV-2,
although reduced expression levels and incorporation of the
R403T mutant CoV-2 S may also contribute. More importantly,
the reverse T403R substitution generally strongly enhanced
RaTG13 S-mediated VSVpp infection without affecting protein
expression levels.
SARS-CoV-2 entry requires sequential cleavage of the S protein
at the S1/S2 and the S2′ cleavage sites to mediate membrane
fusion and infection13,20. The RaTG13 S lacks the polybasic
Fig. 4 Interaction with ACE2 enhances S processing. a Schematic representation of the SARS-CoV-2 S protein: FL (purple), S2 (yellow), S2′ (orange), and
sequence alignments of the SCoV-2 and RaTG13 S1/S2 and S2′ cleavage sites. b Exemplary immunoblots of whole cells lysates (WCLs) and supernatants
of HEK293T cells expressing SCoV-2 S, RaTG13 S, or the indicated mutant that were infected with VSVΔG-GFP in the absence (left) or the presence of a
vector expressing human ACE2 (right). Blots were stained with anti-SCoV-2 S, anti-GAPDH, anti-ACE2, and anti-VSV-M. and quantified for Spike FL, S2,
and S2′ expression. Bars represent the mean of three independent experiments (±SEM). c Automated quantification of GFP fluorescence of A549 ACE2
cells infected with VSVΔG-GFP pseudotyped with indicated SCoV-2 or RaTG13 S in the absence of ACE2. The cells were pre-treated (30min) with 20 µM
of E64-d or Camostat in the highest concentration and diluted in a 1:2 titrational row. Lines represent the mean of three independent experiments (±SEM).
Fig. 5 SCoV-2 S and T403R RaTG13 S allow entry with human but not bat ACE2. a HEK293T cells expressing indicated ACE2 variants or b Tb 1 Lu,
Tadarida brasiliensis derived lung epithelial and Ri 1 Lu huACE2 Rhinolophus affinis derived lung epithelial cells expressing human ACE2 were infected with
VSVΔG-GFP pseudotyped with SCoV-2, RaTG13 or indicated mutant S. Quantification by automatic counting of GFP positive cells. Bars represent the mean
of three independent experiments (±SEM). a, b Two-tailed Student’s t-test with Welch’s correction.
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insertion at the S1/S2 site that enhances furin-mediated cleavage
of the SARS-CoV-2 S (Fig. 4a). Thus, it was expected that the
efficiency of proteolytic processing of RaTG13 S proteins at the
S1/S2 site is reduced (Fig. 4b). It came as surprise, however, that
overexpression of TMPRSS2 only enhanced VSVpp infection
mediated by the SARS-CoV-2 but not by the RaTG13 T403R S
protein (Fig. 2b) since the S2′cleavage site that is targeted by
TMPRSS2 is identical in these S proteins. Instead, processing of
the RaTG13 S at the S2′site was dependent on Cathepsins, which
have also been shown to efficiently cleave the SARS-CoV-2 S in
some cell types27. SARS-CoV-2 replicates in ACE2 expressing
cells. In agreement with published data21, the presence of
ACE2 strongly enhanced proteolytic processing of the SARS-
CoV-2 S (Fig. 4b). Similar effects were observed for RaTG13 S
T403R but not on the WT RaTG13 S suggesting that interaction
with ACE2 has a major impact on proteolytic processing.
It has been shown that the RBD of SARS-CoV-2 S shows
higher homology to the corresponding region of the pangolin
CoV S protein or the recently discovered BANAL-20-52 isolate
from Rhinolophus malayanus in Laos than to RaTG135,6,36.
Whether or not this is a consequence of recombination or con-
vergent evolution is under debate37,38. Notably, both BANAL-20-
52 and Pan CoV S protein contain a positively charged residue at
position 403 and are capable of utilizing human ACE2 for
infection (Fig. 6a, b)36. It was suggested BANAL-20-52 is closer
relative to SARS-CoV-2 than RaTG13, indicating that a change in
residue 403 may have occurred before the emergence of this
strain. Altogether our results suggest that a positively charged
amino acid residue at position 403 in the S protein was a pre-
requisite for efficient zoonotic transmission and pandemic spread
of SARS-CoV-2. Notably, a positively charged residue at the
corresponding position is present in S proteins of most RaTG13-
related bat coronaviruses (Supplementary Fig. 7). Thus, many bat
sarbecoviruses, including the unknown precursor of SARS-CoV-
2, may be fitter for zoonotic transmission than RaTG13. How-
ever, our preliminary data suggest that vaccination might protect
us against such close bat relatives of SARS-CoV-2.
Methods
Cell culture and viruses. All cells were cultured at 37 °C in a 5% CO2 atmosphere.
Human embryonic kidney 293T cells purchased from American type culture col-
lection (ATCC: #CRL3216) were cultivated in Dulbecco’s Modified Eagle Medium
(DMEM, Gibco) supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS, Gibco), 2 mM L-glutamine (PANBiotech), 100 µg/ml streptomycin (PAN-
Biotech) and 100 U/ml penicillin (PANBiotech). Calu-3 (human epithelial lung
adenocarcinoma, kindly provided and verified by Prof. Frick, Ulm University) cells
were cultured in Minimum Essential Medium Eagle (MEM, Sigma) supplemented
with 10% (v/v) FBS (Gibco) (during viral infection) or 20% (v/v) FBS (Gibco)
(during all other times), 100 U/ml penicillin (PAN-Biotech), 100 µg/ml strepto-
mycin (PAN-Biotech), 1 mM sodium pyruvate (Gibco), and 1 mM NEAA (Gibco).
Caco-2 (human epithelial colorectal adenocarcinoma, kindly provided by Prof.
Holger Barth, Ulm University) cells were cultivated in DMEM (Gibco) containing
10% FBS (Gibco), 2 mM glutamine (PANBiotech), 100 µg/ml streptomycin
(PANBiotech), 100 U/ml penicillin (PANBiotech), 1 mM Non-essential amino
acids (NEAA, Gibco), 1 mM sodium pyruvate (Gibco). A549, A549 ACE2, A549
TMPRSS2 and A549 ACE2/TMPRSS2 cells were cultured in DMEM (Gibco)
supplemented with 10% (v/v) FBS (Gibco), 100 U/ml penicillin (PAN-Biotech),
100 µg/ml streptomycin (PAN-Biotech) and 10 µg/ml Puromycin for A549 ACE2
and A549 ACE2/TMPRSS2 and 10 µg/ml Blasticidin for A549 TMPRSS2 and A549
ACE2/TMPRSS2. I1-Hybridoma cells were purchased from ATCC (#CRL-2700)
and cultured in RPMI supplemented with 10% (v/v) heat-inactivated FBS (Gibco),
2 mM L-glutamine (PANBiotech), 100 µg/ml streptomycin (PANBiotech), and 100
U/ml penicillin (PANBiotech). Tb 1 Lu (Tadarida brasiliensis derived lung epi-
thelial) and Ri 1 Lu huACE2 (Rhinolophus affinis derived lung epithelial cells
expressing human ACE2, kindly provided by Marcel A. Müller, were cultured in
DMEM supplemented with 10% (v/v) heat-inactivated FBS (Gibco), 2 mM
L-glutamine (PANBiotech), 100 µg/ml streptomycin (PANBiotech) and 100 U/ml
penicillin (PANBiotech), 2 mM sodium pyruvate (Gibco). Viral isolates BetaCoV/
France/IDF0372/2020 (#014V-03890) was obtained through the European Virus
Archive global.
Pseudoparticle production. To produce pseudotyped VSVΔG-GFP particles,
6*106 HEK 293T cells were seeded 18 h before transfection in 10 cm dishes. The
cells were transfected with 15 µg of a glycoprotein expressing vector using PEI (PEI,
Fig. 6 T403R RaTG13 S is sensitive to EK-1 and sera from vaccinated individuals but not Casivirimab. a−c Automated quantification of GFP
fluorescence of Caco-2 cells infected with VSVΔG-GFP pseudotyped with indicated S variants. The virus was pre-treated (30min) with the indicated
amounts of a EK-1 b Casirivimab (orange), and c Sera of BNT162b2 vaccinated patients. Lines represent the mean of three independent experiments
(±SEM). d Sera of AZ/BNT162b2 and 2xBNT162b2 vaccinated patients with VSVΔG-GFP pseudotyped with RaTG13 S. Lines represent the mean of three
biological replicates. Mean of the inhibition of VSVΔG-GFP pseudotyped with e RaTG13 S by Sera of AZ/BNT162b2 or 2x BNT162b2 vaccinated patients
and f RaTG13 S or SCoV-2 by the Sera of AZ/BNT162b2 (left) or 2x BNT162b2 (right) vaccinated patients Lines represent the mean of three independent
experiments (±SEM).
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1 mg/ml in H2O, Sigma-Aldrich). 24 h post-transfection, the cells were infected
with VSVΔG-GFP particles pseudotyped with VSV G at a MOI of 3. One hour
post-infection, the inoculum was removed. Pseudotyped VSVΔG-GFP particles
were harvested 16 h post-infection. Cell debris was pelleted and removed by cen-
trifugation (500 × g, 4 °C, 5 min). Residual input particles carrying VSV-G were
blocked by adding 10% (v/v) of I1 Hybridoma Supernatant (I1, mouse hybridoma
supernatant from CRL-2700; ATCC) to the cell culture supernatant.
Molecular dynamics simulation. Based on the structure of ACE2-bound to SARS-
CoV-2 spike taken from the Protein Data Bank39: 7KNB (https://www.rcsb.org/
structure/7KNB), the initial atomic positions were obtained. Equilibration (300 K
for 0.5 ns) was performed by ReaxFF (reactive molecular dynamic) simulations40
within the Amsterdam Modelling Suite 2020 (http://www.scm.com). Based on the
equilibrated structure, amino acids from the spike protein were replaced with the
respective amino acids from RaTG13, respectively the modification. After an
additional equilibration (300 K for 0.5 ns) ReaxFF (reactive molecular dynamic)
simulations were performed within the NVT ensemble over 25 ps, while coupling
the system to a Berendsen heat bath (T= 300 K with a coupling constant of 100 fs).
The interaction energy was obtained by averaging over these simulations. For all
visualizations the Visual Molecular Dynamics programme (VMD 1.9.3)41 was used.
Expression constructs. pCG_SARS-CoV-2-Spike-IRES_eGFP, coding the spike
protein of SARS-CoV-2 isolate Wuhan-Hu-1, NCBI reference Sequence
YP_009724390.1, was provided by Stefan Pöhlmann (Göttingen, Germany).
pCG_SARS-CoV-2-Spike C-V5-IRES_eGFP and RaTG13-S (synthesized by Base-
clear) were PCR amplified and subcloned into a pCG-IRES_eGFP expression
construct using the restriction enzymes XbaI and MluI (New England Biolabs). The
SARS-CoV-2 S R403T and RaTG13 S T403R/T403A mutant plasmids were gen-
erated using Q5 Site-Directed Mutagenesis Kit (NEB). ACE2 was synthezised by
Twist bioscience, PCR amplified, and subcloned into a pCG- expression construct
using the restriction enzymes XbaI and MluI (New England Biolabs). ACE2 E37A,
ACE2 D38A, and ACE2 D37A/D38A mutations were introduced by Splice-verlap
Extention PCR using the Thermo scientific Phusion High-Fidelity PCR Kit and
subcloned into a pCG-expression construct. All constructs were verified by
sequence analysis. Primer sequences are listed in Supplementary Data 2.
Transfections. Plasmid DNA was transfected using either calcium phosphate
transfection or Polyethylenimine (PEI, 1 mg/mL in H2O, Sigma-Aldrich) according
to the manufacturer’s recommendations or as described previously42.
Biosafety. All work with bacmid-generated SARS-CoV-2 virus was performed in
the registered BSL3 facility at the Institute of Virology at University Hospital of the
Friedrich-Alexander-University Erlangen-Nuremberg (Az. 821-8760.00-23/90; Az.
821-8791.2.12; Az. 821-8791.2.13). Generation of recombinant SARS-CoV-2 by the
bacmid method was approved by the Central Committee for Biological Safety
(ZKBS) consulting the German Federal Office of Consumer Protection and Food
Safety (BVL) (Az. 45110.2084). Permission for the experiments was granted by the
regional authorities of Lower Franconia (Az. 55.1-8791.27-28-20 and Az. 55.1-
8791.27-29-20).
Cloning of SARS-CoV-2 ΔS bacmid. An anonymized residual respiratory swab
sample from a patient with SARS-CoV-2 infection was used as a template for
genome amplification. Total nucleic acids were extracted on an automated Qiagen
EZ1 robotic workstation using the Qiagen EZ1 virus mini kit v2.0 according to the
manufacturer’s instructions. Genomic viral RNA was reverse transcribed using the
NEB LunaScript RT SuperMix Kit according to the manufacturer’s protocol. Four
overlapping fragments covering the entire viral genome were amplified using the
NEB Q5 High-Fidelity DNA Polymerase. The resulting amplicons were assembled
with a modified pBeloBAC11 backbone, containing CMV and T7 promotors as
well as the HDV ribozyme and bGH polyA signal, using the NEBuilder HiFi DNA
Assembly Cloning Kit. Assembled DNA was electroporated into E. coli
GS1783 strain and resulting clones of pBelo-SARS-CoV-2 were confirmed by
restriction digestion and next-generation sequencing. The viral Spike gene was
replaced with a kanamycin-cassette flanked by SacII restriction sites by homo-
logous recombination using the Lambda-Red Recombination System43. The bac-
mid was linearized with the restriction enzyme SacII, and EGFP or GLuc reporter
cassettes were introduced instead of Spike using the NEBuilder HiFi DNA
Assembly Cloning Kit according to the manufacturer’s instruction. Positive clones
were confirmed by restriction digestion and sequencing.
SARS-CoV-2 ΔS replicon system. HEK293 T cells were seeded in six-well format
and transfected with 3 µg pBelo-SARSCoV-2-dSpike-GLuc-K2 or pBelo-SARS-
CoV-2-dSpike-EGFP and 0.25 µg of each expression construct pLVX-EF1alpha-
SARS-CoV2-N-2xStrep-IRES-Puro, pCG-ACE2, pCAG-T7-RNA-polymerase, and
one pCG- vector encoding the spike protein of SARS-CoV-2, RaTG13 or the
indicated mutant S respectively. Two days after transfection, bright field and
fluorescence microscopy (GFP) images were acquired using the Cytation 3
microplate reader (BioTek). Gaussia luciferase activity in the supernatants was
measured with the Gaussia Luciferase Assay system (Promega) according to the
company’s instructions.
Endpoint titration to determine viral titers. To determine viral titers for sub-
sequent equal infections, viral stocks were serial diluted and Caco-2 cells were
infected with different dilutions. Two days post infection cells were fixed with 4%
PFA (Sigma-Aldrich), washed with PBS-T, and analyzed using the ELISpot/
Immunospot® S6 ULTIMATE UV Image Analyzer (Cellular Technology Limited/
CTL, USA). The dilution where half of the wells are still infected was used for the
calculation of stock concentration.
Cloning and reconstitution of rec-SARS-CoV-2 d6-YFP and d6-YFP-R403T.
As previously described18, an anonymized residual sample from a patient with
SARS-CoV-2 infection was used as a template for genome amplification. Total
nucleic acids of a respiratory swab sample were extracted on an automated Qiagen
EZ1 analyzer using the Qiagen EZ1 virus mini kit v2.0 according to the manu-
facturer’s instructions. Genomic viral RNA was reverse transcribed using the
LunaScript RT SuperMix Kit (NEB) according to the manufacturer’s protocol. Four
overlapping fragments covering the entire viral genome were amplified using the
Q5 High-Fidelity DNA Polymerase (NEB). The resulting amplicons were assem-
bled with a modified pBeloBAC11 backbone (NEB, GenBank Accession #: U51113)
containing CMV and T7 promotors and bGH polyA signal (amplified from
pcDNA4, Thermo Fisher Scientific, V86320) as well as the HDV ribozyme (syn-
thesized as gene block by Integrated DNA Technologies IDT) using the
NEBuilder HiFi DNA Assembly Cloning Kit (NEB). Assembled DNA was elec-
troporated into the E. coli GS1783 strain and resulting clones of pBSCoV2
were confirmed by restriction digestion and next-generation sequencing
(MiSeq™, Illumina).
The viral ORF6 gene was replaced with EYFP by homologous recombination
using the two-step Lambda-Red Recombination System (Tischer et al., 2010;
PMID: 20677001), resulting in pBSCoV2-d6-YFP. The spike R403T point mutation
was generated by two-step Lambda-Red Recombination using pBSCoV2_d6-YFP
as template, resulting in pBSCoV2_d6-YFP_Spike R403T. Restriction digestion and
next-generation sequencing confirmed positive clones of both bacmids.
For virus reconstitution, a co-culture of HEK293T cells stably expressing either
ACE2 (Hoffmann, 2020; PMID: 32142651; cloned into pLV-EF1a-IRES-Blast,
addgene #85133) or the viral N protein (amplified from patient material; cloned
into pLV-EF1a-Blast) and T7-RNA polymerase (amplified from pCAGT7, kind gift
from Marco Thomas; cloned into pLV-EF1a-IRES-Puro, addgene #85132) was
transfected with pBelo-S-CoV-2-d6-YFP or d6-YFP_Spike R403T using GenJet™
Reagent (II) (SL100489, SignaGen® Laboratories, Frederick, MD, USA) according
to the manufacturer’s protocol. Three days post-transfection, the supernatant was
transferred on CaCo-2 cells for passage 1 (P1) virus stocks. Passage 2 (P2) virus
stocks were obtained after infection of CaCo-2 cells with 1:50 volume of P1 virus.
Viral titers were determined by endpoint titration on CaCo-2 cells.
Replication kinetics. To analyze growth kinetics, Caco-2 cells were infected with
either SARS-CoV-2 d6-YFP wild type, SARS-CoV-2 d6-YFP R403T, or mock at an
MOI of 0.005 or 0.02. Therefore, cells were seeded in 96-well format with a cell
density of 2,5 × 104/100 µl and 24 h after seeding infected with respective MOIs.
Supernatant samples were taken at 0, 10, 24, 34, 48, and 72 h post infection and
diluted 1:10 with H2O. Samples were digested with proteinase K (Roche, Switzerland)
for 1 h at 56 °C, and proteinase was heat-inactivated. Afterwards, digested samples
were utilized for RT-qPCR using the Universal Probe One-Step RT-qPCR kit (NEB,
USA) according to manufacturer’s instructions in an Applied Biosystems 7500 Real
Time PCR system (Applied Biosystems, USA). Probes targeting viral polymerase
(RdRP) were 5′-labelled with VIC (2′-chloro-7’phenyl-1,4-dichloro-6-carboxy-fluor-
escein) and 3′-labelled with BMN535 quencher modification (Biomers, Ulm) (Pri-
mers used: fwd: 5′-gtgaaatggtcatgtgtggcgg-3‘, rev: 5′-caaatgttaaaaacactattagcata-3;
probe: 5′-caggtggaacctcatcag-gagatgc3‘)
Whole-cell and cell-free lysates. Whole-cell lysates were prepared by collecting
cells in phosphate-buffered Saline (PBS, Gibco), pelleting (500 g, 4 °C, 5 min),
lysing, and clearing as previously described42. Total protein concentration of the
cleared lysates was measured using the Pierce BCA Protein Assay Kit (Thermo
Scientific) according to the manufacturer’s instructions. Viral particles were filtered
through a 0.45 µm MF-Millipore Filter (Millex) and centrifuged through a 20%
sucrose (Sigma) cushion. The pellet was lysed in transmembrane lysis buffer
already substituted with Protein Sample Loading Buffer (LI-COR).
SDS-PAGE and immunoblotting. SDS-PAGE and immunoblotting was performed
as previously described42. In brief, whole-cell lysates were separated on NuPAGE 4-
12% Bis-Tris Gels (Invitrogen) for 90 min at 120 V and blotted at constant 30 V for
30 min onto Immobilon-FL PVDF membrane (Merck Millipore). After the
transfer, the membrane was blocked in 1% Casein in PBS (Thermo Scientific) and
stained using primary antibodies directed against SARS-CoV-2 S (1:1,000, Biozol,
1A9, #GTX632604), α-SARS-CoV-2 N Sino Biologicals #40588-V08B (1:1000),
anti-SCoV 2 nucleocapsid Invitrogen, #ARC2372 (1:2000), ACE2 (1:1,000, Abcam,
#GTX632604), VSV-M (1:2,000, Absolute Antibody, 23H12, #Ab01404-2.0), V5-
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-27180-0
8 NATURE COMMUNICATIONS |         (2021) 12:6855 | https://doi.org/10.1038/s41467-021-27180-0 | www.nature.com/naturecommunications
tag (1:1,000, Cell Signalling, #13202), Anti-HSP70 Santa Cruz W27/sc-24 (1:1000),
Anti-GFP GenScript A01704-40 (1:1000), GAPDH (1:1,000, BioLegend, #631401),
secondary Anti-human-488 Invitrogen A11013 (1:2000), Anti-mouse-647 Invi-
trogen A31571 (1:2000), Anti-rabbit-647 Invitrogen A21206 (1:2000) and Infrared
Dye labelled secondary antibodies IRDye 800CW Goat anti-Mouse #926-32210,
IRDye 800CW Goat anti-Rat (#926-32219), IRDye 680CW Goat anti-Rabbit
(#925-68071), IRDye 680CW Goat anti-Mouse (#926-68070), IRDye 800CW Goat
anti-Rabbit (#926-32211) all 1:10,000. Proteins were detected using a LI-COR
Odyssey scanner and band intensities were quantified using LI-COR Image Studio
version 5.
ACE2 interaction assay. HEK293T cells expressing the indicated S constructs
were collected after 48 h in phosphate-buffered saline (PBS, Gibco), divided for
simultaneous immunoblotting and ACE2 interaction assay, and pelleted (500 × g,
4 °C, 5 min). For the ACE2 interaction assay, the cells were lysed in NP-40 buffer
(150 mM NaCl, 1% (vol/vol) NP-40, 50 mM HEPES pH 7.4 and protease inhibitor
cocktail (Sigma)) and cell debris pelleted by centrifugation at 20,000 × g for 20 min
at 4 °C. ACE2 coated wells (COVID-19 Spike-ACE2 binding assay II, Ray Bio)
were incubated for 2 h with 50 µl of WCLs and washed extensively with the
provided wash buffer (RayBio, #EL-ITEMB). The wells were incubated 1 h with
100 µl anti-V5(MS) (1:1,000, Cell Signalling, #80076), subsequently washed and
incubated for 1 h with 100 µl anti-MS-HRP (1:1,000, RayBio). After washing, the
samples were incubated with 50 µl of TMB Substrate Solution (RayBio, #EL-TMB)
for 30 min. The reaction was stopped by adding 50 µl Stop Solution (RayBio, #EL-
STOP) and absorption was measured at 450 nm with a baseline correction at
650 nm.
Stem cell culture and intestinal differentiation. Human embryonic stem cell line
HUES8 (Harvard University, Cambridge, MA) was used with permission from the
Robert Koch Institute according to the “79. Genehmigung nach dem Stammzell-
gesetz, AZ 3.04.02/0084”. Cells were cultured on human embryonic stem cell
matrigel (Corning, Corning, NY) in mTeSR Plus medium (STEMCELL Technol-
ogies, Vancouver, Canada) at 5% CO2, 5% O2, and 37 °C. Medium was changed
every other day and cells were split with TrypLE Express (Invitrogen, Carlsbad,
CA) twice a week. For differentiation, 300,000 cells per well were seeded in 24-well
plates coated with growth factor-reduced matrigel (Corning) in mTeSR Plus with
10 mM Y-27632 (STEMCELL Technologies). The next day, differentiation was
started at 80−90% confluency, as described previously44.
Intestinal organoids. To prepare in vitro differentiated organoids for transduc-
tion, matrigel was dissolved in Collagenase/Dispase (Roche, Basel, Switzerland) for
2 h at 37 °C and stopped by cold neutralization solution (DMEM, 1% bovine serum
albumin, and 1% penicillin-streptomycin). Organoids were transferred into 1.5 mL
tubes and infected in 300 μL pseudoparticle containing inoculum. Organoids were
then resuspended in 35 μL cold growth factor–reduced matrigel to generate cell-
matrigel domes in 48-well plates. After 10 min at 37 °C, intestinal growth medium
(DMEM F12 [Gibco, Gaithersburg, MD], 1× B27 supplement [Thermo Fisher
Scientific], 2 mM L-glutamine, 1% penicillin-streptomycin, 40 mM HEPES [Sigma-
Aldrich], 3 μM CHIR99021, 200 nM LDN-193189 [Sigma-Aldrich], 100 ng/mL
hEGF [Novoprotein, Summit, NJ], and 10 μM Y-27632 [STEMCELL Technolo-
gies]) was added and organoids were incubated at 37 °C. The organoids were
imaged using the Cytation 3 cell imaging system and processed with Gen5 and
ImageJ(Fiji) software. For FACS preparation, the matrigel was dissolved and the
extracted organoids were dissolved in Accutase (Stemcell technologies). The cells
were fixed with PBS for 10 min at 4 °C and washed with cold PBS containing 2%
FBS. Flow cytometry analyses were performed using a FACS CANTO II (BD) flow
cytometer. Transduction rates were determined by GFP expression and analyzed
with BD FACSDiva and Flowjow10 software.
Pseudoparticle inhibition. VSVpp inhibition experiments were performed as
previously described45. In brief, Caco-2 cells were infected with 100 µl freshly
produced VSVΔG-GFP pseudo particles, which were preincubated (30 min, 37 °C)
with the indicated amounts of Casivirimab (REGN10933, orange), EK-1 (Core
Facility Functional Peptidomics (UPEP), Ulm University) or Sera of with
BNT162b2 vaccinated donors. GFP-positive cells were automatically quantified
using a Cytation 3 microplate reader (BioTek).
Sera from vaccinated individuals. Blood samples of ChAdOx1-nCoV-19/
BNT162b2 and BNT162b2 vaccinated individuals were obtained after the partici-
pants information and written consent. Samples were collected 13−30 days after
the second dose using S-Monovette Serum Gel tubes (Sarstedt). Before use, the
serum was heat-treated at (56 °C, 30 min). Ethics approval was given by the Ethic
Committee of Ulm University (vote 99/21– FSt/Sta).
Treatment with ATN-161. Caco-2 cells were preincubated with the indicated
amounts of α5β5 integrin Inhibitor ATN-161 (Sigma) for 2 h and infected with
100 µl freshly produced VSVΔG-GFP pseudo particles. Sixteen h post-infection,
GFP positive cells were automatically quantification using a Cytation 3 microplate
reader (BioTek). Calu-3 cells were preincubated with the indicated amounts of
ATN-161 (Sigma) for 2 h and infected with SARS-CoV-2 isolate BetaCoV/France/
IDF0372/2020 (MOI 0.05, 6 h). Forty-eight hours post-infection supernatants were
harvested for qRT-PCR analysis.









GQ153539.1/GQ153540.1/GQ153541.1/GQ153544.1) were performed using
ClustalW46 with a gapOpening penalty of 80. Sequence logos were generated using
R packages ggplot2 and ggseqlogo47.
Statistics. Statistical analyses were performed using GraphPad PRISM 9.2
(GraphPad Software). P-values were determined using a two-tailed Student’s t-test
with Welch’s correction. Unless otherwise stated, data are shown as the mean of at
least three independent experiments ± SEM. See supplemental Data 1 for detail.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The datasets generated during and/or analyzed during the current study are available
from the corresponding authors on request. All Source data are provided in the
Supplementary Information/Source Data file. The SARS-CoV-2 S structure used in this
study is available in the Protein Data Bank (PDB) under accession code 7KNB. Source
data are provided with this paper.
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